Patents Examined by Jeffrey Stucker
-
Patent number: 12215169Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.Type: GrantFiled: December 20, 2021Date of Patent: February 4, 2025Assignee: Bioverativ USA Inc.Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
-
Patent number: 12202895Abstract: The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.Type: GrantFiled: September 12, 2019Date of Patent: January 21, 2025Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, IMMUNE-ONC THERAPEUTICS, INC.Inventors: Zhiqiang An, Chengcheng Zhang, Ningyan Zhang, Xun Gui, Mi Deng, Tao Huang, Qiang Liu, X. Charlene Liao
-
Patent number: 12202840Abstract: The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).Type: GrantFiled: May 20, 2019Date of Patent: January 21, 2025Assignee: AC Immune SAInventors: Sreenivasachary Nampally, Emanuele Gabellieri, Jerome Molette, Heiko Kroth, Cedric Boudou
-
Patent number: 12195554Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of polysialic acid. The antibodies of the present technology are useful in methods for detecting and treating a polysialic acid-associated cancer in a subject in need thereof.Type: GrantFiled: March 13, 2019Date of Patent: January 14, 2025Assignee: Memorial Sloan Kettering Cancer CenterInventors: Linlin Wang, Zhihao Wu, Mahiuddin Ahmed, Sarah M. Taldone, Steven M. Larson, Nai-Kong V. Cheung
-
Patent number: 12194000Abstract: Provided herein is an immunogenic composition comprising a synthetic consensus antigen to chondroitin sulfate proteoglycan 4 (CSPG4) protein which is abundant in many cancers. Also disclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.Type: GrantFiled: August 1, 2019Date of Patent: January 14, 2025Assignee: The Wistar Institute of Anatomy and BiologyInventor: David Weiner
-
Patent number: 12187763Abstract: An affinity chromatography resin comprising an anti-tissue factor antibody or antigen-binding fragment thereof attached to a base resin, and methods of using the same.Type: GrantFiled: February 11, 2021Date of Patent: January 7, 2025Assignee: ImmunityBio, Inc.Inventors: Hing C. Wong, Jin-an Jiao, Caitlin Prendes
-
Patent number: 12187807Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.Type: GrantFiled: August 18, 2023Date of Patent: January 7, 2025Assignee: Visterra, Inc.Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
-
Patent number: 12180284Abstract: The present disclosure relates to PD-L1-binding molecules comprising a Shiga toxin effector region, a PD-L1-binding region, and a T cell epitope, and pharmaceutical compositions thereof. The PD-L1 binding molecules and pharmaceutical compositions thereof have uses for selectively killing specific cells (e.g., PD-L1 positive tumor cells and/or immune cells), for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor cells or immune cells), and as therapeutics for treating or slowing the progression of cancer (e.g., non-small cell lung cancer or squamous cell carcinoma of the head and neck). The present disclosure also relates to clinical methods for use of the disclosed PD-L1 binding molecules for treating a subject in need thereof.Type: GrantFiled: December 16, 2021Date of Patent: December 31, 2024Assignee: Molecular Templates, Inc.Inventors: Eric Poma, Erin Willert, Hilario Ramos, Jensing Liu, Roger Waltzman
-
Patent number: 12173030Abstract: The invention provides compositions and methods for suppressing autoimmune components of neurodegenerative diseases and thereby providing therapeutic effects to patients suffering from such diseases. Compositions and methods include immunosuppressive moieties such as regulatory T cells (Tregs) and proteins expressed by Tregs coupled to a chimeric antigen receptor or protein that specifically binds one or more glial cell markers. Therapeutically effective doses of said compounds for treating neurodegenerative diseases including progressive supranuclear palsy (PSP), Parkinson's disease (PD), Alzheimer's, Huntington's disease, amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), and prion diseases are disclosed.Type: GrantFiled: March 21, 2019Date of Patent: December 24, 2024Assignee: AZTherapies, Inc.Inventor: Philip G. Ashton-Rickardt
-
Patent number: 12173070Abstract: The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.Type: GrantFiled: August 21, 2019Date of Patent: December 24, 2024Assignee: ABL BIO INC.Inventors: Eunyoung Park, Yangsoon Lee, Uijung Jung, YoungKwang Kim, Yeun Ju Kim, Youngdon Pak, Sang Hoon Lee, Weon-Kyoo You, Jaeho Jung, Lei Fang, Wenqing Jiang
-
Patent number: 12168681Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R?. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.Type: GrantFiled: October 25, 2023Date of Patent: December 17, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Jiaxi Wu, Tong Zhang, Samuel Davis, Nicolin Bloch
-
Patent number: 12161669Abstract: The current disclosure provides polypeptide constructs and cells comprising CDR3 regions of ?9. ?2 or both, that selectively bind a J-configuration of CD277 on a target cell. The disclosure also provides pharmaceutical compositions with the disclosed polypeptides or cells and methods of using these compositions in the treatment of cancer.Type: GrantFiled: May 18, 2018Date of Patent: December 10, 2024Assignee: UMC UTRECHT HOLDING B.V.Inventors: Jürgen Herbert Ernst Kuball, Zsolt Sebestyen, Dennis Beringer, Anna Vyborova
-
Patent number: 12153056Abstract: Among the various aspects of the present disclosure is the provision of compositions for and methods of diagnosing, prognosing, and treating diabetes.Type: GrantFiled: July 15, 2020Date of Patent: November 26, 2024Assignee: Washington UniversityInventors: Emil R. Unanue, Xiaoxiao Wan, Cheryl Lichti
-
Patent number: 12145988Abstract: The present disclosure encompasses anti-TREM-2 antibodies that promote TREM-2 activation and methods of using the anti-TREM-2 agonist antibodies therapeutically.Type: GrantFiled: September 11, 2019Date of Patent: November 19, 2024Assignee: Washington UniversityInventors: David Holtzman, Jason Ulrich, Hong Jiang
-
Patent number: 12134771Abstract: A fusion protein which may comprise a first nCas9 fragment, a chimeric insertion fragment, a second nCas9 fragment and two UGI fragments from N-terminus to C-terminus, wherein the chimeric insertion fragment is selected from APOBEC1 fragment or APOBEC3A fragment for cytosine deamination at the target site. The fusion protein may comprise a first nCas9 fragment, a chimeric insertion fragment and a second nCas9 fragment from N-terminus to C-terminus, wherein the chimeric insertion fragment is TadA-TadA* for cytosine deamination at the target site. The present disclosure provides a novel base editing tool that is compatible with insertion of various deaminases on the chimeric sites of nCas9. Compared with nCas9 terminal fusion base editor, the base editing tool of the present invention significantly reduce off-targeting on both DNA and RNA, while maintaining specific targeted base editing efficiency, with higher specificity and favorable industrialization prospects.Type: GrantFiled: January 5, 2023Date of Patent: November 5, 2024Assignee: ShanghaiTech UniversityInventors: Yajing Liu, Shisheng Huang, Xingxu Huang
-
Patent number: 12123006Abstract: The present disclosure relates to the field of biotechnology, in particular to a base editing tool and use thereof. The present disclosure provides a fusion protein comprising a first nCas9 fragment, a chimeric insertion fragment, a second nCas9 fragment and two UGI fragments from N-terminus to C-terminus, wherein the chimeric insertion fragment is selected from APOBEC1 fragment or APOBEC3A fragment. The present disclosure provides a novel base editing tool that is compatible with insertion of various deaminases on the chimeric sites of nCas9. Compared with nCas9 terminal fusion base editor, the base editing tool of the present invention significantly reduce of off-targeting on both DNA and RNA, while maintaining specific targeted base editing efficiency, with higher specificity and favorable industrialization prospects.Type: GrantFiled: May 18, 2021Date of Patent: October 22, 2024Assignee: SHANGHAITECH UNIVERSITYInventors: Yajing Liu, Shisheng Huang, Xingxu Huang
-
Patent number: 12122827Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.Type: GrantFiled: April 26, 2023Date of Patent: October 22, 2024Assignee: ASHER BIOTHERAPEUTICS, INC.Inventors: Yik Andy Yeung, Renee L. Greer, Henry C. Nguyen, David Liu, Byong Kang, Ivana Djuretic
-
Patent number: 12116423Abstract: The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/of impairment.Type: GrantFiled: August 30, 2021Date of Patent: October 15, 2024Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Meredith Hay, John Konhilas, Robin L. Polt, Evan Jones, Lajos Szabo
-
Patent number: 12098209Abstract: An asymmetric fusion protein in which a fragment of an antibody binding to an insulin receptor, an iduronate-2-sulfatase (IDS) enzyme, and an Fc region are fused, and a use thereof are disclosed. The fusion protein can cross the blood-brain barrier (BBB) to deliver the IDS enzyme to the brain. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient can be used as a therapeutic agent for a central nervous system disease and particularly, is expected to prevent and treat various diseases caused by ribosome accumulation.Type: GrantFiled: October 18, 2019Date of Patent: September 24, 2024Assignee: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Ki Joon Cho, Mijung Lee, Eun Jung Song, Ki Su Kim, Kwan Yub Kang, Eui Cheol Cho
-
Patent number: 12098177Abstract: Compositions and methods for NK cell based treatments, and particularly NK cells that express and intracellularly retain IL-2, are presented in which the NK cells are stimulated with a chimeric protein that has a cancer cell targeting portion and an IL-12 portion. Beneficially, such chimeric protein has substantially reduced systemic toxicity and induces IFN-? secretion in a targeted manner. Moreover, chimeric proteins contemplated herein also significantly enhanced IFN-? secretion in NK cells that express and intracellularly retain IL-2 as compared to native NK cells. Preferred chimeric proteins comprise SEQ ID NO:1 or SEQ ID NO:2, and SEQ ID NO:3.Type: GrantFiled: September 5, 2019Date of Patent: September 24, 2024Assignee: NantBio, Inc.Inventors: Kayvan Niazi, Clifford Anders Olson, Shiho Tanaka, Heather McFarlane